Alexion Pharmaceuticals, Inc. (ALXN) Shares Sold by Banque Pictet & Cie SA

Banque Pictet & Cie SA trimmed its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 19.3% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 45,672 shares of the biopharmaceutical company’s stock after selling 10,948 shares during the quarter. Banque Pictet & Cie SA’s holdings in Alexion Pharmaceuticals were worth $6,407,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ALXN. Rathbone Brothers plc grew its stake in shares of Alexion Pharmaceuticals by 2.5% during the 2nd quarter. Rathbone Brothers plc now owns 2,040 shares of the biopharmaceutical company’s stock valued at $248,000 after purchasing an additional 50 shares during the period. Seven Bridges Advisors LLC grew its stake in shares of Alexion Pharmaceuticals by 2.1% during the 2nd quarter. Seven Bridges Advisors LLC now owns 2,638 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 53 shares during the period. Geneva Advisors LLC grew its stake in shares of Alexion Pharmaceuticals by 0.7% during the 2nd quarter. Geneva Advisors LLC now owns 11,408 shares of the biopharmaceutical company’s stock valued at $1,388,000 after purchasing an additional 82 shares during the period. Grandfield & Dodd LLC grew its stake in shares of Alexion Pharmaceuticals by 2.8% during the 2nd quarter. Grandfield & Dodd LLC now owns 3,360 shares of the biopharmaceutical company’s stock valued at $409,000 after purchasing an additional 90 shares during the period. Finally, Evercore Wealth Management LLC grew its stake in shares of Alexion Pharmaceuticals by 8.1% during the 2nd quarter. Evercore Wealth Management LLC now owns 1,665 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 125 shares during the period. Institutional investors own 96.71% of the company’s stock.

In other news, Director Ann M. Veneman sold 835 shares of the stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total transaction of $121,751.35. Following the transaction, the director now owns 5,480 shares of the company’s stock, valued at approximately $799,038.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Julie O’neill sold 4,375 shares of the stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $145.44, for a total value of $636,300.00. Following the transaction, the executive vice president now directly owns 26,092 shares in the company, valued at approximately $3,794,820.48. The disclosure for this sale can be found here. Insiders have sold a total of 16,490 shares of company stock worth $2,337,251 in the last three months. Corporate insiders own 4.35% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Alexion Pharmaceuticals, Inc. (ALXN) Shares Sold by Banque Pictet & Cie SA” was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://sportsperspectives.com/2017/11/18/alexion-pharmaceuticals-inc-alxn-shares-sold-by-banque-pictet-cie-sa.html.

A number of research analysts recently issued reports on ALXN shares. TheStreet downgraded Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Friday, November 10th. Zacks Investment Research upgraded Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price objective for the company in a research note on Tuesday, October 31st. Oppenheimer Holdings, Inc. upgraded Alexion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $175.00 price objective for the company in a research note on Friday, July 28th. Royal Bank Of Canada started coverage on Alexion Pharmaceuticals in a research note on Thursday, September 14th. They set an “outperform” rating and a $161.00 price objective for the company. Finally, Morgan Stanley reiterated an “overweight” rating and set a $153.00 price objective (up from $141.00) on shares of Alexion Pharmaceuticals in a research note on Friday, July 28th. Six research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $154.01.

Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) traded up $0.54 on Friday, hitting $110.87. The stock had a trading volume of 1,937,513 shares, compared to its average volume of 2,296,358. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $96.18 and a fifty-two week high of $149.34. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35. The company has a market cap of $24,650.00, a P/E ratio of 22.49, a price-to-earnings-growth ratio of 1.20 and a beta of 1.22.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.32 by $0.12. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The business had revenue of $859.00 million for the quarter, compared to the consensus estimate of $864.34 million. During the same quarter in the prior year, the company earned $1.23 EPS. The business’s revenue was up 7.5% compared to the same quarter last year. equities analysts forecast that Alexion Pharmaceuticals, Inc. will post 4.81 EPS for the current fiscal year.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply